Cullinan Oncology LLC
$ 18.06
3.20%
21 Jul - close price
- Market Cap 1,075,516,000 USD
- Current Price $ 18.06
- High / Low $ 18.20 / 17.49
- Stock P/E N/A
- Book Value 5.96
- EPS -3.37
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -0.48 %
- 52 Week High 19.43
- 52 Week Low 5.68
About
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$31.55
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-10 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-15 | 2024-03-14 | 2023-11-08 | 2023-08-10 |
| Reported EPS | -0.75 | -0.77 | -0.77 | -1.07 | -0.74 | -0.73 | -0.69 | -0.75 | -0.86 | -0.54 | -0.91 | -0.82 |
| Estimated EPS | -0.8433 | -0.8739 | -0.95 | -0.83 | -0.99 | -0.7423 | -0.81 | -0.73 | -0.99 | -0.96 | -0.92 | -0.97 |
| Surprise | 0.0933 | 0.1039 | 0.18 | -0.24 | 0.25 | 0.0123 | 0.12 | -0.02 | 0.13 | 0.42 | 0.01 | 0.15 |
| Surprise Percentage | 11.0637% | 11.8892% | 18.9474% | -28.9157% | 25.2525% | 1.657% | 14.8148% | -2.7397% | 13.1313% | 43.75% | 1.087% | 15.4639% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.71 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CGEM
2026-07-17 18:54:00
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, highlighting a mid-channel oscillation pattern and a significant 51.8:1 risk-reward setup. It outlines various trading strategies including position trading, momentum breakout, and risk hedging, based on AI-generated signals and multi-timeframe analysis. The report suggests potential choppy conditions due to divergent sentiment across different time horizons.
2026-07-07 21:11:41
Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, executed an exercise-and-sell transaction. She sold 8,000 shares of common stock at a weighted average price of $17.82 per share under a pre-arranged Rule 10b5-1 trading plan and simultaneously exercised stock options for 4,000 shares at $4.30 per share. Following these transactions, Michaelson directly owns 162,844 shares of common stock and holds 112,987 exercisable stock options.
2026-07-07 01:11:42
A Form 144 filing by CGEM (Cullinan Therapeutics, Inc.) indicates a proposed resale of 8,000 shares of common stock from insider-related sources. This includes 4,000 shares from exercised stock options (dated 07/06/2026) and 4,000 shares from Restricted Stock Units (dated 02/22/2024). The filing also notes prior 10b5-1 sales of 8,000 shares on 05/05/2026, generating proceeds of $116,976.02, and names Morgan Stanley Smith Barney LLC as the broker for the proposed sales.
2026-07-06 11:39:40
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, identifying a weak near-term sentiment but strong mid- and long-term outlook. It highlights a significant 53.2:1 risk-reward short setup and provides specific AI-generated trading strategies including position, momentum breakout, and risk hedging, with defined entry, target, and stop-loss levels across various time horizons.
2026-07-02 20:40:58
Cullinan Therapeutics' CFO, Mary Kay Fenton, acquired 1,541 shares of company common stock through the 2021 Employee Stock Purchase Plan. The shares were purchased at $8.60 each, based on 85% of the closing price on January 2, 2026, for the period of January 1 to June 30, 2026. Following this transaction, Fenton directly holds 127,921 shares of Cullinan Therapeutics common stock.
2026-07-02 20:40:58
Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, acquired 2,470 shares of common stock at $8.60 per share through the company's 2021 Employee Stock Purchase Plan. This routine transaction, which occurred between January 1 and June 30, 2026, increases her direct holdings to 130,559 shares. The shares were purchased at 85% of the closing price on January 2, 2026, and the transaction is exempt under Rule 16b-3(c).
